Alpha Tau Medical Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Alpha Tau Medical Ltd. for the month of June 2026, with a specific reporting date of June 23, 2026. The filing serves to distribute a press release regarding a clinical milestone achieved by the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The material event disclosed is the successful treatment of the first recurrent glioblastoma patient outside of the United States using the Company's Alpha DaRT® technology. This procedure took place at Hadassah University Medical Center in Israel.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the standard legal disclaimer that the information is furnished and not deemed "filed" under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the clinical details and patient outcomes of the Alpha DaRT® treatment at Hadassah University Medical Center via the attached press release (Exhibit 99.1).
- Confirm the regulatory status of Alpha DaRT® in Israel and other international markets outside the United States.
- Review the Company's most recent Form 20-F for the latest audited financial position, as this 6-K contains no financial data.